Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALDA responds to SuperBug
Company News Alert for Alda Pharmaceuticals
ALDA Pharmaceuticals Corp.: New "Superbugs" Could Go Global
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 24, 2010) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) ("ALDA" or "the Company") is monitoring reports of new "Superbugs" that are highly resistant to nearly all antibiotics, including penicillin-like antibiotics that possess broad spectrum antibacterial properties and are typically used as a last resort. The new strains of antibiotic-resistant E. coli and Klebsiella were created when genetic material that codes for an antibiotic-digesting enzyme was incorporated from other species. Such genetic "swapping" is common among bacteria and is a major cause of antibiotic resistance. Although primarily observed in Pakistan, India and the UK, similar infections have been reported in US, Canada, Australia and the Netherlands and international researchers are concerned that these new strains could become a major global health problem.
To reduce the spread of these bacteria, health authorities are recommending proper hand hygiene and disinfection procedures. Dr. Terrance Owen, President & CEO comments, "Using effective hand sanitizers and disinfectant products is an important step in keeping one's environment safe. ALDA's products contain 70% ethanol and benzalkonium chloride which have both proven to be very effective against E. coli and other resistant bacteria, such as MRSA. Although the threatened H1N1 pandemic did not materialize, it certainly made people aware of the need for products that can reduce the transmission of infectious diseases. The lessons learned may prove to be very useful as we face ever-increasing numbers of Superbugs."
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the "Act") and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
FOR FURTHER INFORMATION PLEASE CONTACT:
ALDA Pharmaceuticals Corp.
Scott Young
Investor Relations
604-377-5781 or 604-521-8300 Ext 2
604-521-8322(FAX)
scott_young@aldacorp.com
www.aldacorp.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ALDA Pharmaceuticals Amends Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 28, 2010) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF)(PINK SHEETS:APCSF) (the "Company") announces that, in response to prevailing market conditions, the private placement financing announced on April 15, 2010 and revised on April 28, 2010 will be amended to $0.15 per unit. The offering will now be for up to 3,500,000 units of the Company (the "Units") at a price of $0.15 per Unit for proceeds to the Company of up to $525,000. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.30 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.60 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days.
As announced in the April 15th and April 28th news releases, the offering is being made on a private placement basis pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly. Net proceeds from the offering will be used for general corporate purposes.
Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm's length investors, and such insiders' shareholdings in the Company will increase as a result of any such participation. The private placement may close before 21 days following the filing of the material change report regarding this announcement if management determines it to be necessary or desirable for sound business reasons.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company is the Official Supplier of the Vancouver 2010 Olympic Winter Games, Vancouver 2010 Paralympic Winter Games, the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company has also been selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.
ALDA Pharmaceuticals Corp.
Terrance G. Owen, Ph.D., MBA, President & CEO
The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the "Act") and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
FOR FURTHER INFORMATION PLEASE CONTACT:
ALDA Pharmaceuticals Corp.
Scott Young
Investor Relations
604-377-5781 or 604-521-8300 Ext 2
604-521-8322 (FAX)
scott_young@aldacorp.com
www.aldacorp.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Me too
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 19, 2010) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) -
It has been an eventful year and an even more eventful quarter. As shown in the financial statements filed on SEDAR on Friday, January 15, 2010, revenues for the quarter ended December 31, 2009 were nearly $1 million. Compared to corresponding quarters of previous years, this was an 18-fold increase in revenues. This dramatic increase came about for a number of reasons, including the Company becoming an Official Supplier to the Vancouver 2010 Winter Games ("The Winter Games"), concerns about the H1N1 pandemic, health authorities recommending the use of hand sanitizers and a general shortage of hand sanitizers in the market. A host of new customers started stocking ALDA's T36(R) Antiseptic Hand Sanitizer and some also offered T36(R) Disinfectant to their customers. The new retail outlets included Shoppers Drug Marts, Pharmasave, London Drugs, T&T Supermarkets and IGA Marketplace. The Company also became a supplier to Acklands-Grainger, Inc. ("AGI") Canada's largest distributor of industrial, safety and fastener products.
The bulk of the sales were of T36(R) Antiseptic Hand Sanitizer in 60 and 240 ml bottles and 900 and 1,200 ml bags for manual and automatic dispensers which were placed throughout various VANOC locations including the Richmond Olympic Oval and General Motors Place, Vancouver International Airport ("YVR") Grouse Mountain Resorts, the municipalities of New Westminster and Richmond, VANOC headquarters and the Whistler Conference Centre.
As the Winter Games approach, ALDA and T36(R) will be receiving an increased amount of publicity and exposure from posters that are placed throughout the Skytrain system and large billboards at YVR and the Canada-US border. The Company's products will be found throughout the Winter Games and samples will be purchased by VANOC for athletes, volunteers and media representatives.
While sales were much higher than usual, production expenses also increased proportionately and gross margins of approximately 27% were achieved. Management will look for cost savings as demand for products becomes more predictable but the financial commitments to VANOC during the next quarter suggest that profitability will be unlikely. A obvious way to improve margins is for the Company to control its own manufacturing and management will be reviewing this possibility once the demand for product has stabilized and proper projections can be made.
A major effort will be undertaken in sales and marketing now that the hand sanitizer market is less frantic. There are still many potential customers that can be approached and the current customers will be needing assistance from the Company to properly position and promote T36(R) products.
The Company received a substantial amount of publicity since the VANOC agreement was announced including interviews with CBC, CTV and Global TV, Business in Vancouver and BNN. With an estimated 10,000 media representatives attending the Winter Games, more opportunities are likely to arise.
The short-term focus for the Company is to capitalize on the exposure and credibility provided by the Winter Games by taking and holding as much market share as possible. In the medium term, the focus in on achieving registration of the T36(R) products in other jurisdictions that recognize Canadian Drug Identification Numbers ("DIN's"). In the long-term, the Company will continue working towards the registration of T36(R) formulations for therapeutic applications.
Although the last quarter was a turning point for the Company, sales of commercial and consumer products do not match the long term potential of the therapeutic application of ALDA's patented T36(R) technology. One of the first applications to be pursued is the use of T36(R) as a pre-surgical and pre-injection skin antiseptic. An Investigational New Drug ("IND") submission has been presented to the FDA for consideration. Four pre-clinical tests are likely to be required before human clinical trials can begin but the protocols have been established and are included in the submission. The Company is interested in the antiseptic market because Enturia, the company that brought the leading skin antiseptic to the market, was purchased by Cardinal Health for $490 Million in April, 2008.
Other planned therapeutic products include first aid ointments for cuts scrapes, insect bites, etc., a combination of T36(R) and anti-inflammatories, analgesics and anesthetics for use on more intractable skin conditions and infections such as eczema, psoriasis and fungal infections, such as athlete's foot, diaper rash and toenail infections. Treatment for vulvovaginal infections ("VVI's") have been prepared that will combat all classes of infectious organisms rather than just fungi which are responsible for only about one-third of all VVI's. A version of the VVI treatment has been prepared as a microbicidal gel that is designed to prevent the spread of sexually transmitted infections ("STI's").
Management has established a clear plan for the future and is of the opinion that all of the objectives that have been presented in the past have been met as time and funds have allowed. With the past track record as a reference, we are confident that our goals in the future will be met.
Terrance G. Owen, Ph.D., M.B.A., President & CEO
At KFC LOL
Should see many more N/Rs coming for now. On a steady basic.
Yes nice pop .23 right now
ALDA Receives New DIN for Liquid T36(R) Antiseptic Hand Sanitizer
VANCOUVER, BRITISH COLUMBIA, Jan 6, 2009 (Marketwire via COMTEX) -- (Marketwire)
ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("the Company" or "ALDA") announces that a new DIN (02321424) has been issued by Health Canada for T36(R) Antiseptic Hand Sanitizer in liquid form. This new product complements ALDA's previously approved T36(R) Antiseptic Hand Sanitizer Gel and allows the formulation to be manufactured and sold as a spray.
Compared to typical alcohol-based hand sanitizers, ALDA's T36(R) Antiseptic Hand Sanitizer is a unique formula with two active ingredients that provide faster action against a broader range of infectious organisms and offer a long-lasting residual effect.
About ALDA Pharmaceuticals
ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
SOURCE: ALDA Pharmaceuticals Corp.
ALDA Pharmaceuticals Corp. Peter Chen Distribution & Sales Contact (604) 521-8300 Ext. 3 (604) 521-8322 (FAX) Email: peter_chen@aldacorp.com ALDA Pharmaceuticals Corp. Scott Young Investor Relations Contact (604) 288-7222 Email: syoung@freeformcom.com Website: www.aldacorp.com
Copyright (C) 2009 Marketwire. All rights reserved.
Just my thoughts on why I think they release this info when they did. I believe by releasing it after the markets were closed is it would not interfere with other nr’s coming maybe in the next few weeks or even days. This way it would not drive the sp down. It’s good to get this one out early and behind us. It leaves room for other news releases to bring the sp up. I don’t think it would be a good idea to offer stock options @.20 if the sp was around .50 or higher. It just wouldn’t look right. I think TO has a plan and is sticking to it. Let’s hope it’s a good one.
Thanks for the info, surly picks my spirates up :)
Mabey we should re-read the share holders letter.
http://www.aldacorp.com/download/newsreleases/08Q3%20-%20Shareholder%20Letter%20-FINAL.pdf